[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] RE: [IP] Fw:_Cygnus_Launches_Gluco Wa tch®_Biographer_in_ U.S.

I am checking into it.  I called my endo's office today to see about getting a rx.  I think they will cover at least partially(I have BC/BS of GA).  I want one, but I am not sure I am willing to pay $595 + the sensors 16/69.75.  

-----Original Message-----
From: Michael J. Vincent [mailto:email @ redacted]
Sent: Tuesday, April 16, 2002 11:50 AM
To: email @ redacted
Subject: Re: [IP] Fw:_Cygnus_Launches_GlucoWatch._Biographer_in_ U.S.

do the insurance companies cover this???

--- John Ripa <email @ redacted> wrote:
> ----- Original Message -----
> From: <email @ redacted>
> Cc: <recipient list not shown: ;>
> Sent: Monday, April 15, 2002 8:37 AM
> Subject: Cygnus Launches GlucoWatch. Biographer in U.S.
> >
> > This News Release will be posted on Cygnus' website at
> http://www.cygn.com/press/news.html as soon as possible after it is
> released
> to the media.
> >
> > Please note: This email service is intended solely to distribute
> information, and is not designed to be an interactive email system.
> Please
> note that replies to Cygnus' email announcement will not be responded
> to.
> For additional information, please contact Cygnus by phone at (650)
> 369-4300, fax at (650) 599-2503 or visit our homepage at:
> www.cygn.com.
> >
> > Cygnus Launches GlucoWatch(R) Biographer in U.S.
> > The only FDA-approved product that provides
> > frequent, automatic and non-invasive measurement of glucose levels
> >
> > Redwood City, CA - April 15, 2002 - Cygnus, Inc. (Nasdaq: CYGN)
> today
> announced the U.S. market launch of the GlucoWatch(R) Biographer, the
> only
> product approved by the U.S. Food and Drug Administration (FDA) for
> consumers designed to measure glucose levels frequently,
> automatically and
> non-invasively.  The frequent and automatic measurements provided by
> the
> GlucoWatch Biographer can identify trends and track patterns in
> fluctuating
> glucose levels that would be difficult for people with diabetes and
> their
> health care teams to detect with current testing techniques alone.
> >
> > "We are very excited about making the GlucoWatch Biographer
> available in
> the United States.  It represents the most significant technological
> breakthrough in glucose monitoring since the transition from urine
> dip
> sticks to blood meters about twenty years ago.  Numerous clinical
> studies
> have demonstrated the health benefits of frequent glucose testing and
> more
> frequent insulin injections.  Unfortunately, the vast majority of
> people
> with diabetes do not test their glucose levels frequently enough and
> fluctuating glucose levels make it extremely difficult for detection
> with
> current testing methods alone," stated John C Hodgman, Chairman,
> Chief
> Executive Officer and President of Cygnus, Inc.  "There is an unmet
> need for
> a product that can readily provide frequent glucose measurements. 
> The
> GlucoWatch Biographer can be the solution for millions of people with
> diabetes."
> >
> > The GlucoWatch Biographer is the first and only glucose monitoring
> system
> that provides readings frequently, automatically and non-invasively,
> up to
> three times an hour, for up to twelve hours day or night.  The
> Biographer is
> a glucose monitoring device designed to detect trends and track
> patterns in
> glucose levels in adults (ages 18 and older) with diabetes.  This
> device is
> intended for use by patients at home and in health care facilities. 
> It is
> for prescription use only.  The Biographer is intended for use an
> adjunctive
> device to supplement, not replace, information obtained from standard
> home
> glucose monitoring devices.  The GlucoWatch Biographer is indicated
> for use
> in detection and assessment of episodes of hyperglycemia and
> hypoglycemia,
> facilitating both acute and long-term therapy adjustments, which may
> minimize these excursions. Interpretation of Biographer results
> should be
> based on the trends and patterns seen within several sequential
> readings
> over time.
> >
> > The GlucoWatch Biographer differs from other glucose monitoring
> systems in
> several ways.  It is non-invasive, collecting glucose through the
> skin, not
> from blood.  It automatically measures and displays glucose levels
> and
> detects trends and patterns in glucose levels as opposed to a single,
> discrete reading.  It has alert systems to inform users when glucose
> levels
> are too high, too low or declining rapidly.  The Biographer also
> stores up
> to 4,000 glucose values in an electronic diary that can be reviewed
> at the
> touch of a button or uploaded into a software program to enable
> detailed
> analysis of glucose fluctuations.
> >
> > "The GlucoWatch Biographer represents a tremendous advance in
> diabetes
> management," said Steven Edelman, M.D., Professor of Medicine,
> Division of
> Diabetes and Metabolism, University of California San Diego School of
> Medicine and Veterans Affairs, and the founder and Director of the
> non-profit organization Taking Control of Your DiabetesTM.  "Most
> people
> with diabetes are not fully aware of the frequent fluctuations they
> have in
> their glucose levels.  I have many patients who will benefit greatly
> from
> the insight they will gain from the additional information provided
> by the
> Biographer," added Dr. Edelman.
> >
> > The GlucoWatch Biographer will be available for sale through direct
> mail,
> not through retail pharmacies.  People interested in learning more
> about the
> GlucoWatch Biographer and how to order can request information by
> calling
> toll free 1-866-GLWATCH (1-866-459-2824) or by visiting
> www.glucowatch.com.
> To obtain a GlucoWatch Biographer, adults with diabetes will need to
> consult
> a health care professional to get a prescription, complete the order
> form
> contained in the Introductory Training Brochure and complete a
> questionnaire
> to be sure the device is right for them.
> >
> > The GlucoWatch Biographer consists of two main parts: the durable
> Biographer, which is the watch-like device that attaches to a
> person's
> forearm, and the AutoSensor, the disposable component that attaches
> to the
> back of the Biographer and allows for glucose monitoring for up to 12
> hours.
> The price of the Starter Kit, which includes the GlucoWatch
> Biographer,
> instructional video, user guide, battery charger and two rechargeable
> batteries, as well as other accessories, is $595. AutoSensors are
> sold in
> cartons of 16 and sell for $69.75.  Also available for sale at $35.00
> is the
> GlucoWatch(R) Analyzer, FDA-approved software that downloads data
> retrieved
> by the individual's Biographer into a personal computer for display
> and
> storage of data.  The software uses the data to generate statistical
> reports
> and graphs that are designed to create a comprehensive picture of an
> individual's recent glucose level history and allow for analysis of
> trends
> and patterns in glucose levels.  Purchases can only be made by using
> or MasterCard(R) credit cards.  At the completion of the transaction,
> the
> GlucoWatch Biographer and associated products will be shipped
> directly to
> the consumer.
> >
> > Cygnus and Sankyo have been collaborating closely on sales and
> marketing
> efforts under an agreement signed in November 2001. The co-promotion
> agreement covers the GlucoWatch Biographer and other similar glucose
> monitoring products in the United States. The agreement calls for
> Sankyo to
> provide a 50-person specialty sales force, well-versed in diabetes
> and its
> treatment, to leverage Sankyo's already established relationships
> with
> physicians having the highest potential for prescribing the
> GlucoWatch
> Biographer. Sankyo may also provide broad market coverage through
> their 450
> primary care sales representatives.  In addition, Sankyo may deploy
> 20
> managed care account managers to obtain insurance reimbursement for
> the
> GlucoWatch Biographer and 20 medical managers who would communicate
> key
> scientific data to medical professionals.
> >
> > The World Health Organization estimates there are 125 million
> people
> worldwide with diabetes. This number has increased 15% in the last 10
> years
> and is expected to double by 2025. In the United States,
> approximately 10
> million Americans have been diagnosed with diabetes and each year
> approximately 13,000 children are diagnosed. Diabetes is a leading
> cause of
> death in the United States, and the complications of uncontrolled
> diabetes
> result in an estimated $100 billion in medical costs annually. The
> current
> worldwide market for glucose measuring products is estimated at
> between $3
> billion and $4 billion, and it is expected to exceed $4.7 billion in
> 2002.
> The United States is estimated to account for 50%-60% of all sales,
> while
> Western Europe accounts for approximately 30% of sales.
> >
> > Cygnus, Inc. is engaged in the development and manufacture of
> diagnostic
> medical devices, utilizing proprietary technologies to satisfy unmet
> medical
> needs cost-effectively. The first such device is a frequent,
> automatic and
> non-invasive glucose monitoring device, the first-generation
> GlucoWatch
> Biographer. A supplemental pre-market approval (PMA) submission is
> currently
> under expedited review by the FDA for use of the GlucoWatch
> Biographer by
> children and adolescents (ages 7-17). The GlucoWatch Biographer has
> also
> received the CE mark permitting sales in the European Union, and
> Cygnus is
> currently selling the first-generation product in the United Kingdom.
> >
> > Sankyo Pharma Inc. is a wholly owned subsidiary of Sankyo Co. Ltd.,
> the
> second largest drug company in Japan.  Sankyo is a recognized
> research-based
> company and a source of new therapeutic agents, including drugs for
> cardiovascular disease and diabetes.
> >
> > More information about Cygnus can be found at the corporate web
> site:
> http://www.cygn.com. Additional information about the GlucoWatch
> Biographer
> can be obtained by calling the Company's toll-free number,
> 1-866-GLWATCH, or
> by visiting http://www.glucowatch.com.
> >
> > Some of the statements in this news release are forward-looking
> statements
> that involve risks and uncertainties. These forward-looking
> statements
> include statements about the Company's plans, objectives,
> expectations,
> intentions and assumptions and other statements contained in this
> news
> release that are not statements of historical fact. Forward-looking
> statements include, but are not limited to, statements about the
> Company's
> ability to manufacture and scale-up commercially the GlucoWatch
> Biographer,
> the Company's plans for commercialization alliances, the Company's
> ability
> to achieve market acceptance of the GlucoWatch Biographer, and the
> Company's
> plans for enhancements and possible manufacturing changes through the
> regulatory process. In some cases, you can identify these statements
> by
> words such as "may," "will," "should," "estimates," "predicts,"
> "potential,"
> "continues," "strategy," "believes," "anticipates," "plans,"
> "expects,"
> "intends" and similar expressions. Cygnus cannot guarantee future
> results,
> levels of activity, performance or achievements. Actual results and
> the
> timing of certain events may differ significantly from the results
> discussed
> in the forward-looking statements. The Company refers you to the
> documents
> the Company files from time to time with the Securities and Exchange
> Commission, including the Company's Annual Report on Form 10-K,
> Quarterly
> Reports on Form 10-Q and Current Reports on Form 8-K, which contain
> descriptions of certain factors that could cause the Company's actual
> results to differ from the Company's current expectations and any
> forward-looking statements contained in this news release.
> "GlucoWatch" is a
> registered trademark of Cygnus, Inc.
> >
> >
> >
> > To unsubscribe click here
> > http://www.shareholder.com/visitors/unsubscribe.cfm?companyID=CYGN
> >
> > service provided by Shareholder.com.
> ----------------------------------------------------------
> for HELP or to subscribe/unsubscribe, contact:
> HELP@insulin-pumpers.org
> send a DONATION http://www.Insulin-Pumpers.org/donate.shtml

Do You Yahoo!?
Yahoo! Tax Center - online filing with TurboTax
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml